Dimensional Fund Advisors LP Has $490,000 Position in MoonLake Immunotherapeutics $MLTX

Key Points

• Dimensional Fund Advisors reduced its MoonLake Immunotherapeutics stake by 85.7% in the first quarter, selling 157,245 shares and retaining 26,307 shares valued at approximately $490,000.
• Institutional investors hold 93.85% of MLTX, while insiders sold 344,800 shares worth about $6.82 million over the past 90 days, including sales by the CEO and an insider under pre-arranged Rule 10b5-1 plans.
• MoonLake reported a quarterly loss of $0.84 per share, beating estimates of $0.91, and analysts have an average “Hold” rating with a $24.57 price target versus the stock’s recent opening price of $16.47.

Dimensional Fund Advisors LP cut its holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 85.7% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 26,307 shares of the company's stock after selling 157,245 shares during the quarter. Dimensional Fund Advisors LP's holdings in MoonLake Immunotherapeutics were worth $490,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Kestra Advisory Services LLC acquired a new stake in MoonLake Immunotherapeutics in the 4th quarter valued at about $26,000. Bank of America Corp DE grew its stake in shares of MoonLake Immunotherapeutics by 64.7% during the third quarter. Bank of America Corp DE now owns 4,532 shares of the company's stock valued at $32,000 after purchasing an additional 1,781 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of MoonLake Immunotherapeutics by 115.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company's stock valued at $42,000 after purchasing an additional 3,166 shares in the last quarter. Russell Investments Group Ltd. raised its position in MoonLake Immunotherapeutics by 45.4% in the 4th quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company's stock worth $45,000 after purchasing an additional 1,069 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new position in MoonLake Immunotherapeutics during the 4th quarter worth $47,000. Institutional investors and hedge funds own 93.85% of the company's stock.

Insider Activity at MoonLake Immunotherapeutics

In other MoonLake Immunotherapeutics news, insider Kristian Reich sold 50,000 shares of the stock in a transaction on Tuesday, July 21st. The shares were sold at an average price of $20.02, for a total value of $1,001,000.00. Following the sale, the insider directly owned 2,714,746 shares in the company, valued at approximately $54,349,214.92. This trade represents a 1.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Da Silva Jorge Santos sold 68,289 shares of the stock in a transaction on Friday, July 10th. The stock was sold at an average price of $20.02, for a total transaction of $1,367,145.78. Following the completion of the sale, the chief executive officer owned 2,774,893 shares in the company, valued at approximately $55,553,357.86. This trade represents a 2.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 344,800 shares of company stock valued at $6,820,071 in the last ninety days. Insiders own 10.40% of the company's stock.

MoonLake Immunotherapeutics Price Performance

MoonLake Immunotherapeutics stock opened at $16.47 on Friday. The firm has a market capitalization of $1.40 billion, a P/E ratio of -4.29 and a beta of 1.06. MoonLake Immunotherapeutics has a 1 year low of $5.95 and a 1 year high of $62.75. The business has a 50-day moving average of $18.91 and a 200-day moving average of $17.89. The company has a current ratio of 12.56, a quick ratio of 8.60 and a debt-to-equity ratio of 0.23.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.84) EPS for the quarter, beating analysts' consensus estimates of ($0.91) by $0.07. On average, equities analysts anticipate that MoonLake Immunotherapeutics will post -3.34 EPS for the current year.

Analyst Upgrades and Downgrades

MLTX has been the subject of several research reports. Needham & Company LLC lifted their target price on MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the company a "buy" rating in a research note on Tuesday, May 12th. HC Wainwright boosted their price objective on MoonLake Immunotherapeutics from $45.00 to $50.00 and gave the stock a "buy" rating in a report on Thursday. Leerink Partners raised their target price on shares of MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the company an "outperform" rating in a research note on Wednesday, July 1st. BTIG Research reissued a "buy" rating and set a $30.00 price target on shares of MoonLake Immunotherapeutics in a research note on Tuesday, June 9th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of MoonLake Immunotherapeutics in a research note on Friday, August 7th. Ten investment analysts have rated the stock with a Buy rating, four have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, MoonLake Immunotherapeutics has an average rating of "Hold" and an average price target of $24.57.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source